ATLANTA - Sunday, December 9th 2012 MLN9708: First oral proteasome inhibitor to enter clinical evaluation in front-line multiple myeloma in combination with lenalidomide, dexamethasone(BUSINESS...
INGELHEIM, Germany - Friday, October 26th 2012 (BUSINESS WIRE)-- For Non-U.S. and Non-U.K. MediaBoehringer Ingelheim and Eli Lilly and Companytoday announced that the European...